Amatuximab is a chimeric monoclonal antibody designed for the treatment of cancer.It was developed by Morphotek, Inc.
Mechanism of action
Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.
in vivo
In tumor xenograft studies, combination treatment with amatuximab plus chemotherapy led to a greater reduction in the growth of mesothelin-expressing tumors than either Amatuximab or chemotherapy alone[1].
